Table 1 Sponge derived bioactive molecules in clinical and preclinical trials
From: Dragon exploration system on marine sponge compounds interactions
Name | Sponge | Disease | Status |
|---|---|---|---|
Discodermolide | Discodermia dissoluta | Cancer | Phase I |
E7389 | Lissodendoryx sp | Cancer | Phase III [14] |
HTI-285 (hemiasterlin derivative) | Cymbastella sp | Cancer | Phase II |
KRN-7000 | Agelas mauritianus | Cancer | Phase I |
Peloruside A | Mycale hentscheli | Cancer | Preclinical |
Salicylihalimides A | Haliclona sp | Cancer | Preclinical |
Laulimalide | Cacospongia mycofijiensis | Cancer | Preclinical |
Variolins | Kirkpatrickia variolosa | Cancer | Preclinical |
Dictyodendrins | Dictyodendrilla verongiformis | Cancer | Preclinical |
Manoalide | Luffariaella variabilis | Antipsoriatic | Phase II/discontinued |
Bengamide derivative | Jaspis sp | Cancer | Phase I/discontinued |
Girolline | Pseudaxinyssa cantharella | Cancer | Phase I/discontinued |